What is tesamorelin used for? In the United States, its labeled use is reducing excess fat deep inside the abdomen of adults with HIV who have lipodystrophy, a change in where the body stores fat. It is not a general weight-loss shot.
Providers sometimes consider tesamorelin for other problems involving visceral fat, the fat packed around the organs, or fatty liver. That is off-label care, meaning use outside the product’s official label. The strongest evidence still comes from people living with HIV, so that boundary matters.
What is tesamorelin used for on the label?
The current Egrifta WR prescribing information, revised in March 2025, says the medication is indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy. This doesn’t mean every kind of belly fat. It refers mainly to visceral fat, which sits behind the abdominal wall around internal organs, rather than subcutaneous fat, the softer layer just under the skin.
A 2010 pooled analysis by Falutz and colleagues combined two phase 3 trials involving 806 adults with HIV and excess abdominal fat. At 26 weeks, the reduction in visceral fat was 15.4% greater with tesamorelin than with placebo, while the difference in subcutaneous abdominal fat was not significant (Falutz et al., Journal of Clinical Endocrinology & Metabolism 2010). That selective result is the heart of the medication’s labeled purpose. A closer look at whether tesamorelin works covers the trial results in more depth.
How does it target that kind of fat?
Tesamorelin is a growth hormone-releasing factor analogue, a lab-made version of a signal the brain already uses. It tells the pituitary gland, a small gland at the base of the brain, to release the body’s own growth hormone in pulses. That raises IGF-1, a growth signal made mostly by the liver, and changes how the body handles fat.
That makes tesamorelin different from human growth hormone itself. It is also not a steroid or a GLP-1 medication such as semaglutide. Those medicines work through different signals and are prescribed for different reasons.
The scale may barely move even when visceral fat changes. The Egrifta WR label calls the medicine weight-neutral and specifically says it is not indicated for weight-loss management.
What do off-label uses mean here?
A provider may consider tesamorelin when visceral fat is a concern outside the narrow HIV-lipodystrophy label. But there is much less direct trial evidence for people without HIV. A study result in one population can’t simply be carried over to everyone with abdominal fat.
Fatty liver has a more concrete, though still limited, research signal. In a 2019 randomized trial, 61 adults with HIV and nonalcoholic fatty liver disease were enrolled. After 12 months, liver fat fell by 4.1 percentage points more with tesamorelin than with placebo, equal to a 37% relative reduction from baseline (Stanley et al., The Lancet HIV 2019). The trial was small, and every participant had HIV. It does not establish tesamorelin as a general fatty-liver treatment for people without HIV.
This is the useful line to hold: a provider can weigh an off-label use against one person’s history, but “studied for” is not the same as “established treatment for everyone.”
What changed in 2026?
As of September 6, 2026, the day this article was written, a meta-analysis published July 31 had combined four randomized trials with 909 adults who had HIV and lipodystrophy. It found a mean visceral-fat reduction of 21.47 square centimeters versus placebo, but no meaningful change in BMI; follow-up lasted no longer than 52 weeks, and more than 8 in 10 participants were men (Ditta et al., Journal of the International Association of Providers of AIDS Care 2026). The new analysis strengthens the narrow visceral-fat answer. It does not broaden the evidence to routine weight loss.
The same 90-day search found an FDA warning letter dated August 24, 2026 that named tesamorelin and a tesamorelin/ipamorelin blend sold online among products the agency described as unapproved new drugs. That action concerned the seller’s products and claims; it did not change Egrifta’s labeled use. It also shows why evidence for a brand product should not be assumed to apply to an online vial or a blend. Tesamorelin and ipamorelin together explains what adding the second peptide changes.
What tesamorelin is not meant to do
Tesamorelin’s narrow use gets blurred online. A few distinctions keep expectations grounded:
- It is not labeled for general weight management or cosmetic spot reduction.
- It does not treat HIV and does not replace antiretroviral medication.
- It is not a substitute for nutrition, movement, or standard care for fatty liver.
- It is not established as a bodybuilding, longevity, or performance treatment.
A change in IGF-1 is a monitoring result, not a wellness score. More is not automatically better.
What a provider checks before prescribing
Tesamorelin changes growth-hormone signaling, so the medical review is more than a discussion about body fat. The Egrifta WR label lists pregnancy, active cancer, certain pituitary problems, and a serious allergy to the ingredients as reasons the brand should not be used. It also calls for attention to blood sugar and IGF-1.
Fluid retention can show up as swelling, joint pain, or carpal-tunnel symptoms. Injection-site reactions can happen too. A provider looks at those risks, current medicines, prior cancer history, glucose levels, and the reason treatment is being considered. The fuller tesamorelin side-effects guide explains what monitoring is for.
The prescriber sets the formulation, dose, and follow-up plan. Published study protocols are evidence, not personal instructions.
The product and the prescription route matter
Tesamorelin through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The brand label and brand-trial evidence do not automatically transfer to a compounded preparation.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request and not everyone qualifies. When a prescription is written, a licensed U.S. compounding pharmacy prepares and dispenses it.
That distinction is easy to miss when every vial carries the same molecule’s name. The practical difference is accountability: a prescriber has reviewed the person, a pharmacy has a dispensing record, and there is a clinical relationship for follow-up.